Vedanta Biosciences raises $27M in Series C round
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
The company also appointed to its board former Novartis CEO Joe Jimenez, who was involved with the Swiss drugmaker's hiring of former Trump attorney Michael Cohen.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Massachusetts-based Kaleido Biosciences has brought in $101 million in Series C funding to advance its microbiome-targeting therapeutic pipeline.
Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.
Companies that target the microbiome for various therapies have rallied $840 million since 2010, according to a new report by Silicon Valley Bank that analyzes the wider progress of the field.
Seres Therapeutics had a rough 2016, but it's optimistic that those hard-earned lessons could now help it succeed. Following discussions with FDA, it has moved into a pivotal Phase 3 trial in recurrent C. difficile infections.
From money-back guarantees to a surprising source of funding, MedCity INVEST presenters and panelists discussed some of the major trends influencing the biopharma sector in 2017.
More funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.
Despite many ambitious efforts to modulate the human microbiome, our knowledge of this microscopic world remains extremely limited. A new University of Chicago spin-out, Gusto, wants to change that with a computational modeling platform that can predict how different bacteria operate, what they do, and how they interact in a given ecosystem.
Axial Biotherapeutics is the latest startup working to manipulate the microbiome as a means to treat disease. The Caltech spin-out just announced $19.15 million in Series A funding to tackle a range of central nervous system disorders.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
With $15.5 million more in the bank, San Francisco startup uBiome is on a mission to scale and diversify its consumer gut bacteria tests into clinically actionable diagnostics.
Second Genome uses genomics, computational biology and phenotypic screening to identify the molecular mechanisms of the microbiome that cause disease.
Two Nobel laureates are scientific advisors to New York City startup Kallyope, which is examining the function of the gut-brain axis.
Symberix just raised $500,000 in SBIR grants to build out its microbiome-based drugs.
Flagship Ventures has launched new company Evelo Therapeutics, which will be using an understanding of the microbiome to created targeted cancer treatment.